Medical Device Cybersecurity Massachusetts

The FDA now expects a complete cybersecurity package with every 510(k), PMA, or De Novo submission for a connected device. Miss a Software Bill of Materials, a threat model, or a Secure Product Development Framework, and your review can stall before it starts. MedLaunch helps Massachusetts medical device developers turn these cybersecurity requirements into clear, manageable steps, so your submission holds up the first time.

The Cybersecurity Hurdles Standing Between You and Approval

Since Section 524B of the FD&C Act took effect, cybersecurity is a gating requirement for any “cyber device.” That includes almost any device with software that can connect to the internet through Wi-Fi, Bluetooth, cellular, USB, or a cloud service.

For teams new to medical device regulation, the documentation load can feel steep. The FDA expects you to show your work across the full product lifecycle.

Common roadblocks include:

• Premarket cybersecurity documentation for your 510(k), PMA, or De Novo, built to current FDA guidance.
• A machine-readable SBOM listing every commercial, open-source, and off-the-shelf software component, with support levels and end-of-support dates.
• Threat modeling and security risk assessments that identify vulnerabilities and define countermeasures.
• Security testing evidence, including vulnerability testing, fuzz testing, and independent penetration testing.
• A postmarket plan to monitor, identify, and patch vulnerabilities within a reasonable time.

A gap in any one area can trigger a Refusal to Accept or a round of additional information requests. Each cycle costs weeks you may not have.

MedLaunch closes those gaps before a reviewer finds them. We build your cybersecurity evidence into a clear, submission-ready package, so your device stays on schedule and your team stays focused on the product.

Our Medical Device Cybersecurity Services

We support Massachusetts developers across the full cybersecurity lifecycle, from the first design decision through postmarket monitoring. Each service maps directly to current FDA expectations.

Cybersecurity Gap Analysis

You cannot fix what you have not measured. Our gap analysis compares your current cybersecurity practices against Section 524B and the FDA’s premarket guidance.

We review:

• Your Secure Product Development Framework (SPDF) and how it fits your quality system under the QMSR.
• Your existing documentation against the FDA’s recommended submission elements.
• Your security architecture views, including the global system view, multi-patient harm view, and updatability view.

You receive a clear report and a prioritized action plan, so you know exactly what to build next.

Threat Modeling and Security Risk Management

Strong cybersecurity starts at design. We help you build a threat model that identifies your security objectives, risks, and vulnerabilities across the whole system.

Our support includes:

• Threat modeling aligned with recognized standards such as AAMI TIR57 and ANSI/AAMI SW96.
• Cybersecurity risk assessments focused on exploitability, so you can judge and control residual risk.
• A Software Bill of Materials (SBOM) built to accepted minimum elements, with component support levels and end-of-support dates.
• Security testing planning, covering vulnerability testing, fuzz testing, attack surface analysis, and independent penetration testing.

The result is a defensible risk record that ties your evidence, your architecture, and your claims together.

Post-Market Cybersecurity Surveillance

Your responsibilities continue after clearance. Section 524B requires a plan to monitor and address vulnerabilities across the life of your device.

We help you put that plan in place:

• A postmarket monitoring plan to identify and address vulnerabilities within a reasonable time.
• Coordinated vulnerability disclosure (CVD) procedures so researchers and users can report issues clearly.
• A patch and update process with a justified timeline for regular updates and out-of-cycle fixes for critical, uncontrolled risks.
• Metrics and tracking, such as time to patch and time to deploy, that show the FDA that your program works.

This keeps your device compliant and your patients protected long after launch.

A Partner Who Knows the Massachusetts MedTech Community

MedLaunch works alongside local teams as a hands-on partner. We understand the pace at which Massachusetts developers move and the standards they need to meet. We speak both languages your project needs: the technical detail your engineers care about, and the timeline and budget clarity your stakeholders expect.

Whether you are a startup building your first connected device or an established firm adding cloud features to a legacy product, we tailor our support to your stage and your goals.

Get Your Cybersecurity Submission Right the First Time

Cybersecurity requirements are now a make-or-break part of your FDA submission. Handled early, they protect your timeline and build reviewer confidence. Handled late, they can delay your launch by months.

You do not have to work through Section 524B alone. MedLaunch turns FDA cybersecurity requirements into clear, manageable steps, from your first gap analysis through postmarket surveillance. As a partner who knows both the regulations and the Massachusetts MedTech community, we help your device reach the market on time and to standard. Schedule a consultation today.